Alan Bash

“Carvicti continued to deliver solid global growth during the quarter. Net trade sales increased approximately 36% year over year to approximately $710 million, reflecting continued demand growth globally.”

“I want to start by briefly addressing the leadership transition announced last month. As you all know, Dr. Ying Wang stepped down as Chief Executive Officer and member of the Board, and the Board appointed me to serve as Interim Chief Executive Officer.”

“I'll start with a high-level view of Carvicti's commercial performance and then spend time on what's driving growth beneath the surface. In Q1, Carvicti delivered another quarter of sequential growth, reflecting continued share gains, strong site productivity, and increasing penetration in earlier lines of therapy.”

“Turning to our fourth quarter results, Carvicti net trade sales grew 66% year over year and 6% from the third quarter due to seasonality of shipments.”